Author(s):
Harsh Vardhan Singh, Mo. Shahid, Ashish Jain, Akhlesh Kumar Singhai
Email(s):
hvardhan1020@gmail.com
DOI:
10.52711/2321-5836.2024.00034 
Address:
Harsh Vardhan Singh, Mo. Shahid, Ashish Jain, Akhlesh Kumar Singhai
School of Pharmacy, LNCT University, Bhopal - 462042, India.
*Corresponding Author
Published In:
Volume - 16,
Issue - 3,
Year - 2024
ABSTRACT:
Breast cancer, a prevalent malignancy affecting women globally, is characterized by the uncontrolled growth of abnormal cells in the breast tissue with various risk factors such as age, genetic predisposition, hormonal influences, and lifestyle choices, early detection remains paramount for effective treatment. Diagnostic modalities, including mammography, ultrasound, and biopsy, play crucial roles in identifying the disease at its nascent stages. Therapeutic approaches for breast cancer encompass a multidisciplinary strategy, incorporating surgery, radiation therapy, chemotherapy, hormonal therapy, and targeted therapies. Surgical interventions, such as lumpectomy or mastectomy, aim to remove the tumour, while radiation therapy targets residual cancer cells. Chemotherapy utilizes cytotoxic drugs to destroy rapidly dividing cancer cells, and hormonal therapies modulate hormone receptor-positive tumours. Targeted therapies, including monoclonal antibodies and small molecule inhibitors, focus on specific molecular pathways implicated in cancer progression. Advancements in precision medicine have led to the development of personalized therapies tailored to individual patients based on genetic and molecular profiling. Immunotherapy, harnessing the body's immune system to combat cancer cells, emerges as a promising frontier in breast cancer treatment. In this review article, we have studied how breast cancer is evolved and how we can cure it together with the therapies involved in the management of breast cancer.
Cite this article:
Harsh Vardhan Singh, Mo. Shahid, Ashish Jain, Akhlesh Kumar Singhai. Breast Cancer: From Etiology to Therapeutic Interventions. Research Journal of Pharmacology and Pharmacodynamics.2024;16(3):199-7. doi: 10.52711/2321-5836.2024.00034
Cite(Electronic):
Harsh Vardhan Singh, Mo. Shahid, Ashish Jain, Akhlesh Kumar Singhai. Breast Cancer: From Etiology to Therapeutic Interventions. Research Journal of Pharmacology and Pharmacodynamics.2024;16(3):199-7. doi: 10.52711/2321-5836.2024.00034 Available on: https://rjppd.org/AbstractView.aspx?PID=2024-16-3-11
REFERENCES:
1. Anand, P, Kunnumakkara AB, Sundaram C, Hari kumar KB, Tharakan ST, Lai OS, Sung B and Aggarwal BB. Cancer is a preventable disease that requires major lifestyle changes. Pharm. Res 2008; 25: 2097-116.doi.org/10.1007/s11095-008-9661-9
2. Agarwal SP, Rao YN and Gupta S. Fifty years of cancer control in India, Ministry of Health and Family Welfare Government of India November. 2002.
3. Ames BN, Gold LS, Willett WC. The causes and prevention of cancer. Proceedings of the National Academy of Sciences 1995; 92 (12): 5258–65. doi: 10.1073/pnas.92.12.5258.
4. NaynaAbhang, Joe Lopez. Health Belief Model for Social Marketing of Breast Self-Examination – A Review of Literature. Asian Journal of Management. 2018; 9(1): 493-499. DOI: 10.5958/2321-5763.2018. 00077.X
5. Arjun Patidar, S.C. Shivhare, UmeshAteneriya, SonuChoudhary. A Comprehensive Review on Breast Cancer. Asian J. Nur. Edu. & Research 2(1): Jan.-March 2012; Page 28-32.
6. Sharma GN, Dave R, Sanadya J, Sharma P, Sharma KK. Various types and management of breast cancer: an overview. J Adv Pharm Technol Res 2010; 1:109-26.
7. Newton M, Newton RN. The let-down reflex in human lactation. The Journal of Pediatrics 1948; 33: 698–704.
8. Matthes ZG, Urban C, Vallejo A. Anatomy of the nipple and breast ducts. Gland Surgery 2016; 5: 32–36.
9. Watson CJ, Khaled WT. Mammary development in the embryo and adult: A journey of morphogenesis and commitment. Development. 2008; 135: 995–1003.
10. WeitzelJN, Lagos VI, Cullinane CA, Gambol PJ, Culver JO. Limited Family Structure and BRCA gene mutation status in single cases of breast cancer, JAMA. 2007; 297:2587-2595.
11. Corcos D. Unbalanced replication as a major source of genetic instability in cancer cells, American Journal of Blood Research. 2012; 2:160–9.
12. Tan M, Yu D. Molecular Mechanisms of ErbB2-Mediated Breast Cancer Chemo-resistance. Breast Cancer Chemo-sensitivity. Advances in Experimental Medicine and Biology. 2007; 608:119–29.
13. V. N. Dange, S. J. Shid, C.S. Magdum, S.K. Mohite. A Review on Breast cancer: An Overview. Asian J. Pharm. Res. 2017; 7(1): 49-51.DOI: 10.5958/2231-5691.2017.00008.9.
14. Petit T, Dufour P, Tannock I. A critical evaluation of the role of aromatase inhibitors as adjuvant therapy for postmenopausal women with breast cancer. Endocrine-Related Cancer. 2011; 18: R79-89.
15. Khalil DN, Smith EL, Brentjens RJ, Wolchok JD. The future of cancer treatment: immunomodulation, CARs and combination immunotherapy. Nature Reviews. Clinical Oncology. 2016; 13: 273–90.
16. GK Sudhakar, VasudevPai, Arvind Pai. An overview on current Strategies in Breast Cancer Therapy. Research J. Pharmacology and Pharmacodynamics. 2013; 5(6): 353-355.
17. Perry, Michael J. The Chemotherapy source book. Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins. 2008
18. Goodrich DW, Wang NP, Qian YW, Lee EY, Lee WH. The retinoblastoma gene product regulates progression through the G1 phase of the cell cycle. Cell. 1991; 67: 293–302.
19. Hall AG, Tilby MJ. Mechanisms of action of, and modes of resistance to, alkylating agents used in the treatment of haematological malignancies. Blood Reviews. 1992; 6: 163–73.
20. TacarO, Sriamornsak P, Dass CR. Doxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systems. The Journal of Pharmacy and Pharmacology. 2013; 65: 157–170.
21. Nabholtz JM. Long-term safety of aromatase inhibitors in the treatment of breast cancer. Ther Clin Risk Manag. 2008; 4:189-204.
22. Ravindra B. Saudagar, Nachiket S. Dighe, Deepak S. Musmade, Vinayak M. Gaware, D. A. Jain. SERM’s in Treatment of Breast Cancer. Asian J. Pharm. Res. 2011; 1(4): 81-86.
23. Harbeck N, Beckmann MW, Rody A, Schneeweiss A, Müller V, Fehm T, et al. HER2 Dimerization Inhibitor Pertuzumab - Mode of Action and Clinical Data in Breast Cancer. Breast Care. 2013; 8: 49–55.
24. Francisco LM, Sage PT, Sharpe AH. The PD-1 pathway in tolerance and autoimmunity. Immunol Rev. 2010; 236:219-42.
25. Samson K. LEE011 CDK Inhibitor Showing Early Promise in Drug-Resistant Cancers. Oncology Times. 2014; 36: 39–40.
26. Inoue K, Yuasa H. Molecular basis for pharmacokinetics and pharmacodynamics of methotrexate in rheumatoid arthritis therapy. Drug Metabolism and Pharmacokinetics. 2014; 29: 12-19.
27. Ekta Khare, Aditi Sharma, Anurima Chowdhury, Shailendra Singh Narwariya. Potential of Natural products for Chemoprevention of Breast Cancer.Research Journal of Pharmacognosy and Phytochemistry. 2023; 15(4):305-0. doi: 10.52711/0975-4385.2023.00048
28. Zhang M, Holman CD, Huang JP, Xie X. Green tea and the prevention of breast cancer: a case-control study in Southeast China. Carcinogenesis. 2007; 28:1074-8.
29. Chen J, Saggar JK, Corey P, & Thompson LU. Flaxseed and pure secoisolariciresinoldiglucoside, but not flaxseed hull, reduce human breast tumor growth (MCF-7) in athymic mice. The Journal of Nutrition. 2009; 139: 2061-2066.
30. Lopes CM, Dourado A, Oliveira R. Phytotherapy and Nutritional Supplements on Breast Cancer. Bio Med Research International. 2017; 2017:1–42.
31. Akshay R. Yadav, Shrinivas K. Mohite. Anticancer Activity of Psidiumguajava Leaf Extracts on Breast Cancer Cell Line. Res. J. Pharma. Dosage Forms and Tech. 2020; 12(4): 298-300.DOI: 10.5958/0975-4377.2020.00049. X.
32. Parveen N, Mohammed A, Shukla R, Thanikachalam PV, Jain G, Kesharwani P. Immunoliposomes as an emerging nanocarrier for breast cancer therapy. European Polymer Journal. 2023; 184: 111781.doi: 10.1016/j.eurpolymj.2022.111781
33. Garrido CI, Adam AA, Lameirinhas A, Blandez JF, Candela NV, Lluch A, Bermejo B, Sancenón F, Cejalvo JM, Martínez MR, Eroles P. Delivery of miR-200c-3p Using Tumor-Targeted Mesoporous Silica Nanoparticles for Breast Cancer Therapy. ACS Appl Mater Interfaces. 2023; 15: 38323-38334.doi: 10.1021/acsami.3c07541.
34. Farghadani R, Naidu R. Curcumin as an Enhancer of Therapeutic Efficiency of Chemotherapy Drugs in Breast Cancer. International Journal of Molecular Sciences. 2022; 23: 2144. doi: 10.3390/ijms23042144
35. Yap KM, Sekar M, Fuloria S, Wu YS, Gan SH, Mat Rani NNI, Subramaniyan V, Kokare C, Lum PT, Begum MY, Mani S, Meenakshi DU, Sathasivam KV, Fuloria NK. Drug Delivery of Natural Products. Through Nanocarriers for Effective Breast Cancer Therapy: A Comprehensive Review of Literature. Int J Nanomedicine. 2021; 16: 7891-7941.doi: 10.2147/IJN.S328135.
36. Hernando C, Ortega MB, Tapia M, Moragon S, Martínez MT, Eroles P, Garrido CI, Adam AA, Lluch A, Bermejo B, et al. Oral Selective Estrogen Receptor Degraders (SERDs) as a Novel Breast Cancer Therapy: Present and Future from a Clinical Perspective. International Journal of Molecular Sciences. 2021; 22: 7812.doi: 10.3390/ijms22157812.
37. Juan A, Cimas FJ, Bravo I, Pandiella A, Ocana A, Alonso-Moreno C. An Overview of Antibody Conjugated Polymeric Nanoparticles for Breast Cancer Therapy. Pharmaceutics. 2020; 12: 802.doi: 10.3390/pharmaceutics12090802.
38. Tadahiko S, Hiroji I. Adjuvant and neoadjuvant therapy for breast cancer, Japanese Journal of Clinical Oncology. 2020; 50:225–229.doi: 10.1093/jjco/hyz213.
39. Lu YS, Im SA, Colleoni M, Franke F, Bardia A, Cardoso F, Harbeck N, Hurvitz S, Chow L, Sohn J, Lee KS, Campos-Gomez S, Villanueva Vazquez R, Jung KH, Babu KG, Wheatley-Price P, De Laurentiis M, Im YH, Kuemmel S, El-Saghir N, O'Regan R, Gasch C, Solovieff N, Wang C, Wang Y, Chakravartty A, Ji Y, Tripathy D. Updated Overall Survival of Ribociclib plus Endocrine Therapy versus Endocrine Therapy Alone in Pre- and Perimenopausal Patients with HR+/HER2- Advanced Breast Cancer in MONALEESA-7: A Phase III Randomized Clinical Trial. Clin Cancer Res. 2022; 28: 851-859.doi: 10.1158/1078-0432.CCR-21-3032.
40. Yin H, Xiong G, Guo S, Xu C, Xu R, Guo P, Shu D. Delivery of Anti-miRNA for Triple-Negative Breast Cancer Therapy Using RNA Nanoparticles Targeting Stem Cell Marker CD133. MolTher. 2019; 27: 1252-1261.doi: 10.1016/j.ymthe.2019.04.018.
41. Noam P, Mariana B, Georges El-H, Werbrouck E, Piccart M. Treatment of advanced HER2-positive breast cancer: and beyond. Cancer Treatment Reviews. 2018; 67: 10-20.doi: 10.1016/j.ctrv.2018.04.016.
42. Jameera BA, Jubie S, Nanjan MJ. Estrogen receptor agonists/antagonists in breast cancer therapy: A critical review. Bioorg Chem. 2017; 71: 257-274.doi: 10.1016/j.bioorg.2017.02.011.
43. He L, Gu J, Lim LY, Yuan ZX, Mo J. Nanomedicine-Mediated Therapies to Target Breast Cancer Stem Cells. Front Pharmacol. 2016; 13: 313.doi: 10.3389/fphar.2016.00313
44. Linda SS, Alberto MM, Lucio C, Massimo Libra, Ferdinando Nicoletti, Stephen L. Abrams, James A. McCubrey, The therapeutic potential of mTor inhibitors in breast cancer, British Journal of Clinical Pharmacology 2016; 82: 1189-1212.doi: 10.1111/bcp.12958.
45. Manhong L, Yong L, Xiaohui H, Xizhi L. Captopril-polyethyleneimine conjugate modified gold nanoparticles for co-delivery of drug and gene in anti-angiogenesis breast cancer therapy. Journal of Biomaterials Science. 2015; 26:813–827.doi: 10.1080/09205063.2015.1057991.
46. Zhao J, Krzysztof B, Hongxu L, Aydan D, Gottschaldt M, Stenzel MH. Fructose-coated nanoparticles: a promising drug nanocarrier for triple-negative breast cancer therapy. Chem. Commun. 2014; 50:15928–15931.doi.org/10.1039/C4CC06651K.